bioAffinity Technologies’ (BIAF) Hold Rating Reiterated at Maxim Group

bioAffinity Technologies (NASDAQ:BIAF)‘s stock had its “hold” rating reiterated by stock analysts at Maxim Group in a research note issued to investors on Tuesday,Benzinga reports.

bioAffinity Technologies Trading Down 0.7 %

Shares of NASDAQ:BIAF opened at $0.26 on Tuesday. The business’s 50 day simple moving average is $0.57 and its 200 day simple moving average is $1.07. bioAffinity Technologies has a 1 year low of $0.24 and a 1 year high of $3.16. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01. The company has a market capitalization of $4.05 million, a P/E ratio of -0.32 and a beta of 3.12.

Institutional Investors Weigh In On bioAffinity Technologies

An institutional investor recently raised its position in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC raised its position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,304 shares of the company’s stock after acquiring an additional 26,304 shares during the quarter. Sheaff Brock Investment Advisors LLC owned about 0.30% of bioAffinity Technologies worth $42,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 1.64% of the company’s stock.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.